Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 10;40(9):265.
doi: 10.1007/s12032-023-02128-0.

Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis

Farzaneh Karimi  1 , Omid Azadbakht  2 , Ali Veisi  3 , Mohammad Sabaghan  4 , Maryam Owjfard  5   6 , Ebrahim Kharazinejad  7 , Negar Dinarvand  8
Affiliations
Review

Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis

Farzaneh Karimi et al. Med Oncol. .

Abstract

Ovarian cancer (OC) is a highly fatal gynecologic malignancy, often diagnosed at an advanced stage which presents significant challenges for disease management. The clinical application of conventional tissue biopsy methods and serological biomarkers has limitations for the diagnosis and prognosis of OC patients. Liquid biopsy is a novel sampling method that involves analyzing distinctive tumor elements secreted into the peripheral blood. Growing evidence suggests that liquid biopsy methods such as circulating tumor cells, cell-free RNA, circulating tumor DNA, exosomes, and tumor-educated platelets may improve early prognosis and diagnosis of OC, leading to enhanced therapeutic management of the disease. This study reviewed the evidence demonstrating the utility of liquid biopsy components in OC prognosis and diagnosis, and evaluated the current advantages and limitations of these methods. Additionally, the existing obstacles and crucial topics for future studies utilizing liquid biopsy in OC patients were discussed.

Keywords: Diagnosis; Extracellular vesicles; Liquid biopsy; Ovarian cancer; Prognosis.

PubMed Disclaimer

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–49. - PubMed
    1. Brown Y, Hua S, Tanwar PSJMB. Extracellular matrix in high-grade serous ovarian cancer: advances in understanding of carcinogenesis and cancer biology. Matrix Biol. 2023;118:16–46. - PubMed
    1. Zhu JW, Charkhchi P, Akbari MR. Potential clinical utility of liquid biopsies in ovarian cancer. Mol Cancer. 2022;21(1):1–24.
    1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–96. - PubMed
    1. Köbel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, et al. Ovarian carcinoma histotype: strengths and limitations of integrating morphology with immunohistochemical predictions. Int J Gynecol Pathol. 2019;38(4):353. - PubMed

LinkOut - more resources